Lista de obras - Ana Arance - Dominio Público Uruguay

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

artículo científico publicado en 2014

Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process

artículo científico publicado en 2007

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

artículo científico publicado en 2017

Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors.

artículo científico publicado en 2018

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

artículo científico publicado en 2018

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

artículo científico publicado en 2017

CDC group IV c-2 infection in a stem cell transplant recipient

artículo científico publicado en 1997

Clinical implications of the intrinsic molecular subtypes of breast cancer

artículo científico publicado en 2015

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

artículo científico publicado en 2014

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

artículo científico publicado en 2018

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

artículo científico publicado en 2015

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

artículo científico publicado en 2017

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

artículo científico publicado en 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

artículo científico publicado en 2017

Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.

artículo científico publicado en 2016

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

artículo científico publicado en 2017

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

artículo científico publicado en 2018

Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study

artículo científico publicado en 2015

Genomic analysis and clinical management of adolescent cutaneous melanoma

artículo científico publicado en 2017

Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

artículo científico publicado en 2013

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).

artículo científico publicado en 2017

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

artículo científico publicado en 2015

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

artículo científico publicado en 2017

Infomelanoma 2020: an online digital application designed to assist health professionals for melanoma treatment.

artículo científico publicado en 2017

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

artículo científico publicado en 2021

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

artículo científico publicado en 2017

Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.

artículo científico publicado en 2016

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

artículo científico publicado en 2014

Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer

scientific article published on 15 August 2014

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis.

artículo científico publicado en 2016

Nivolumab in previously untreated melanoma without BRAF mutation

artículo científico publicado en 2015

O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study

artículo científico publicado en 2000

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

artículo científico publicado en 2017

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

artículo científico publicado en 2018

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

artículo científico publicado en 2017

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

artículo científico publicado en 2016

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

artículo científico publicado en 2017

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

artículo científico publicado en 2017

Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer

artículo científico publicado en 2000

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

artículo científico publicado en 2003

Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

artículo científico publicado en 2017

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

artículo científico publicado en 2018

Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).

artículo científico publicado en 2017

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

artículo científico publicado en 2015

SEOM clinical guideline for the management of malignant melanoma (2017).

artículo científico publicado en 2017

SEOM guidelines for the management of Malignant Melanoma 2015

artículo científico publicado en 2015

Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience

artículo científico publicado en 2016

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

artículo científico publicado en 2013

Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.

artículo científico publicado en 2016

Vasculitic neuropathy induced by pembrolizumab

artículo científico publicado en 2016

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

artículo científico publicado en 2016

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

artículo científico publicado en 2014

[New treatments for germ cell tumors with poor prognosis]

scientific article published on 01 July 2000

Lista de obras de Ana Arance

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

CDC group IV c-2 infection in a stem cell transplant recipient

Clinical implications of the intrinsic molecular subtypes of breast cancer

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study

Genomic analysis and clinical management of adolescent cutaneous melanoma

Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

Infomelanoma 2020: an online digital application designed to assist health professionals for melanoma treatment.

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis.

Nivolumab in previously untreated melanoma without BRAF mutation

O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

SEOM clinical guideline for the management of malignant melanoma (2017).

SEOM guidelines for the management of Malignant Melanoma 2015

Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.

Vasculitic neuropathy induced by pembrolizumab

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

[New treatments for germ cell tumors with poor prognosis]